Initially, the company will manufacture fluid bed and granulation technology in the new plant. So far, GEA Pharma has manufactured only outside India, primarily in Europe.
GEA Pharma claimed that the new factory will offer strategic low-cost manufacturing, enabling the company to provide European-quality processing equipment in the Indian market.
Navin Lakhanpaul, regional manager for GEA Pharma Systems in Vadodara, said: “India is a high-growth market that’s very price-sensitive and susceptible to technology. This low-cost manufacturing base will allow us to provide the high-end, European quality products our Indian customers need at prices that are appropriate to the local market.
“In most projects, around 70% of the project value is in peripheral equipment. It’s also essential for us to keep the technical know-how close at hand to help us maintain the efficient after-sales service our customers expect.”
Mr Lakhanpaul said that the effects of low-cost manufacturing, locally-sourced peripheral equipment and reduced transportation costs could reduce the equipment price by around 40% or more when compared with equipment bought from Europe.
Frans Maas, division director of sales and marketing at GEA Pharma Systems, aid: “The factory in Vadodora is an important development for our company and part of our strategy for sustainable global supply,” reported Power and Bulk.